Kostiukova 2003.

Methods	Six‐week, single‐centre, randomised study.
Participants	Psychiatric inpatients meeting ICD‐10 for recurrent depressive disorder without psychotic features, with a minimum baseline score of 19 on the HRSD‐17. Age range: 18‐65 years old. Exclusion criteria: not stated.
Interventions	Fluvoxamine: 30 participants. Amitriptyline: 30 participants. Fluvoxamine dose range: 50‐300 mg/day. Amitriptyline dose range: 50‐250 mg/day.
Outcomes	HRSD‐17. Total dropout, dropout due to inefficiency, dropout due to side effects, side effect profile.
Funded by pharmaceutical companies	Unclear.
Fluvoxamine as an investigational or comparator drug	As an investigational drug.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details.
Allocation concealment (selection bias)	Unclear risk	No details.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	No details.
Incomplete outcome data (attrition bias) All outcomes	High risk	Study endpoint: 7/30 missing from fluvoxamine group (4 due to lack of efficacy, 3 due to adverse effects); 8/30 missing from control group (3 due to lack of efficacy, 5 due to adverse effects).
Selective reporting (reporting bias)	High risk	SDs of endpoint/change score for depression were not reported.